durvalumab
astrazeneca
 outcome by primary tumor locations of topaz1 study is presented #wcgic2022 at barcelona,spain
tsubgroup analysis showed addition of durvalumab to cisgem was associated with overall survival in advanced btc irrespective of primary tumor locations. . 
@Georgetown Universty MC. medical oncologist specialized in gastrointestinal cancer and researcher on liver cancer and biliary cancer. All opinions are mine.